More about

Atopic Dermatitis

Clinical Guidance
Atopic Dermatitis
Comorbidities

Comorbidities Associated with Atopic Dermatitis

Jonathan I. Silverberg, MD, PhD, MPH

Free clinical reference tool that includes treatment options; diagnosis information; guidelines; and more.

Clinical Guidance
Atopic Dermatitis
Treatment Guidelines

Atopic Dermatitis Guidelines

Jonathan I. Silverberg, MD, PhD, MPH

Free clinical reference tool that includes treatment options; diagnosis information; guidelines; and more.

Clinical Guidance
Atopic Dermatitis
Presentation and Diagnosis

Diagnosis and Evaluation

Jonathan I. Silverberg, MD, PhD, MPH

Free clinical reference tool that includes treatment options; diagnosis information; guidelines; and more.

Clinical Guidance
Atopic Dermatitis
Presentation and Diagnosis

Clinical Presentation

Jonathan I. Silverberg, MD, PhD, MPH

Free clinical reference tool that includes treatment options; diagnosis information; guidelines; and more.

Clinical Guidance
Atopic Dermatitis
Overview

Environmental Risk Factors

Jonathan I. Silverberg, MD, PhD, MPH

Free clinical reference tool that includes treatment options; diagnosis information; guidelines; and more.

Clinical Guidance
Atopic Dermatitis
Overview

Epidemiology

Jonathan I. Silverberg, MD, PhD, MPH

Free clinical reference tool that includes treatment options; diagnosis information; guidelines; and more.

News
June 30, 2024
1 min read
Save

Worst Itch Numeric Rating Scale proves valid, reliable for prurigo nodularis

Worst Itch Numeric Rating Scale proves valid, reliable for prurigo nodularis

A new study found that the Worst Itch Numeric Rating Scale is a valid and reliable instrument to capture itch data of patients with prurigo nodularis.

News
June 25, 2024
1 min read
Save

Vtama cream approved for treatment of psoriasis, atopic dermatitis in Japan

Vtama cream approved for treatment of psoriasis, atopic dermatitis in Japan

Vtama cream 1% has been approved in Japan for the treatment of adults with psoriasis as well as patients aged 12 years and older with atopic dermatitis, Dermavant Sciences announced in a press release.

News
June 20, 2024
2 min read
Save

Ruxolitinib cream 1.5% exhibits long-term safety in pediatric atopic dermatitis

Ruxolitinib cream 1.5% exhibits long-term safety in pediatric atopic dermatitis

Year-long ruxolitinib cream 1.5% treatment among children aged 2 to 11 years with extensive moderate to severe atopic dermatitis is safe, according to results presented at the Revolutionizing Atopic Dermatitis Conference.

CME
Monograph

Moderate-to-Severe Atopic Dermatitis: Separating Fact From Myth in Primary Care

Moderate-to-Severe Atopic Dermatitis: Separating Fact From Myth in Primary Care
0.75 CME
0.75 AAPA
45 MINS
$0 FEE
View more